Bone marrow stem cell therapy in multiple sclerosis: potential mechanisms of repair and protection
Bone marrow stem cell therapy in multiple sclerosis: potential mechanisms of repair and protection
批准号:
MR/K004166/1
负责人:
Neil Scolding
金额:
$38.32万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2013
资助国家:
英国
项目状态:
已结题
起止时间:
2013 至 --
中文摘要
多发性硬化症是一种大脑和脊髓疾病,影响着全球250万人,每年给欧盟经济造成90亿欧元的损失,原因是进行性神经功能障碍。它通常始于暂时复发,然后是缓解期,但超过80%的患者会发展为永久性的进行性残疾;40%的患者需要在10年内使用轮椅。目前还没有治疗方法可以逆转、阻止甚至延缓多发性硬化症的进行性残疾。干细胞疗法为减少这种不治之症的残疾提供了新的可能性。这些好处将对患者产生巨大的个人影响,也会产生严重的积极经济影响。寻求真正的干细胞疗法的紧迫性还在于对抗不受监管的商业干细胞诊所的欺骗性吸引力,这些诊所从绝望的患者那里收取大笔资金进行可疑的、有时甚至是危险的“治疗”。多年来,我们一直在探索人类骨髓来源的[BM]干细胞与多发性硬化症的潜力,最初是在实验室,最近是在一项小型(第一阶段)临床试验中。我们关注这些细胞的原因有很多。它们相对容易获得;它们似乎是安全的;我们和其他研究已经证实它们具有广泛的有价值的治疗特性。在骨髓中存在各种干细胞亚型,它们似乎具有许多有价值的能力,对骨髓干细胞抑制炎症有潜在的益处。它们刺激大脑和脊髓中的其他修复细胞,促进组织修复,并分泌生长因子--保护脑细胞免受伤害。此外,在静脉注射后,它们成功地渗透到大脑和脊髓(这是与任何神经疾病相关的重要特性,在这些疾病中,获得受影响的脑组织是一个严重的障碍)。最后但并非最不重要的是,患者使用自己的骨髓细胞治疗,避免了组织排斥的严重困难。我们假设骨髓细胞疗法对长期存在的多发性硬化症提供了持久的好处。我们相信这些细胞在多种方面都有帮助,而且不止一种干细胞类型参与了治疗效果。在布里斯托尔,我们最近完成了世界上第一批修复性骨髓细胞治疗6例慢性MS(www.nature.com/clpt/journal/v87/n6/full/clpt201044a.html).患者的可行性/安全性试验之一安全性得到了证实,患者似乎稳定了下来(尽管在这样一个相对短期的研究中,这必须被视为未经证实)。密集的重复测试,测量大脑和脊髓中不同路径的神经传导,显示每个患者在12个月时都有统计上的显著改善。虽然这些结果非常初步,只涉及非常少数的患者,但这些结果至少提高了在受损神经系统内产生显著(尽管非常部分)潜在修复效果的可能性。我们认为,这迫切需要进一步的测试--既要加速患者的益处,又要开始提高治疗效果。因此,我们提出了一项MS骨髓干细胞研究计划,包括(1)一项规模更大的(‘第二阶段’)对照试验,治疗70名长期存在的MS患者;(2)平行研究作用机制,研究并比较接受治疗的MS患者和对照受试者的骨髓细胞,确定各种细胞类型中哪些有助于疗效,哪些特定修复机制(S)是重要的。我们的试验得到了美国一家基金会的资助;这项申请寻求资金,以开展这些细胞如何工作的研究--以及重要的是,多发性硬化症患者的骨髓细胞与非多发性硬化症患者的骨髓细胞之间是否存在差异。我们希望这些研究不仅能证实这种方法的治疗益处,还能为改善这种新的、令人兴奋的治疗方法的规模和影响提供基础。
英文摘要
Multiple sclerosis - MS - is a disease of the brain and spinal cord that affects 2.5m people worldwide, costing the EU economy E9 billion/year, from the consequences of progressive neurological disability. It usually starts with episodes of temporary relapse followed by periods of remission, but over 80% of patients develop permanent, progressive disability; 40% need a wheelchair within 10 years. There are no treatments that reverse, halt or even slow progressive disability in MS.Stem cell therapy offers new possibilities for reducing disability in this incurable disease. Such benefits would have huge personal impact for patients, and also serious positive economic implications. Urgency in pursuing authentic stem cell therapies also lies in countering the deceptive attraction of unregulated commercial stem cell clinics, which take large sums of money from desperate patients for dubious and occasionally hazardous 'treatments'.We have for some years explored the potential of human bone marrow-derived [BM] stem cells in relation to MS, initially in the laboratory, and lately in a small ('phase 1') clinical trial. We concentrate on these cells for many reasons. They are relatively accessible; they appear safe; and our and other studies have confirmed that they have a wide range of valuable therapeutic properties.There are various sub-types of stem cell present within BM, and they appear to possess many valuable capacities of potential benefit for MS. BM stem cells dampen inflammation. They stimulate other repair cells present in the brain and spinal cord, they promote tissue repair, and they secrete growth factors - which protect brain cells against injury. Also, after injection into a vein, they successfully infiltrate the brain and spinal cord (a vital property relating to any neurological disease, where access to affected brain tissue is a serious hurdle). Last but not least, patients are treated using their own BM cells, avoiding the serious difficulties of tissue rejection.We hypothesise that BM cell therapy in longstanding MS offers durable benefit. We believe these cells help in multiple ways, and that more than one stem cell type is involved in the therapeutic effect.In Bristol, we recently completed one of the first feasibility/safety trials in the world of reparative BM cell therapy in 6 patients with chronic MS (www.nature.com/clpt/journal/v87/n6/full/clpt201044a.html). Safety was confirmed, and patients appeared to stabilise (though in such a relatively short term study, this must be viewed as unproven). Intensive repeated tests, measuring nerve conduction in various pathways in the brain and in the spinal cord, showed statistically significant improvements at 12 months in every patient. While highly preliminary and involving only a very small number of patients, these results at least raise the possibility of a significant (though very partial) underlying repair effect within the damaged nervous system.We believe this urgently requires further testing - both to accelerate benefit towards patients, and to begin improving therapeutic efficacy. We therefore propose a programme of MS BM stem cell research, including (1) a much larger ('phase two') controlled trial, treating 70 patients with longstanding MS; and (2) a parallel study of the mechanisms of action, studying and comparing BM cells from treated MS patients and control subjects, establishing which of the various cell types contribute to efficacy, and which specific repair mechanism(s) are important. Our trial has been funded by a grant from a USA foundation; this application seeks funding to carry out studies into how these cells work - and, importantly, whether there are differences between BM cells from MS patients and those from non-MS 'controls'. We hope these studies will not only confirm the therapeutic benefit of this approach, but also provide the basis for improving the magnitude and impact of this novel, exciting treatment.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis.
KIF5A和易感基因型作为多发性硬化症的预测生物标志物的贡献。
DOI:
10.1007/s00415-020-10373-w
发表时间:
2021-06
期刊:
Journal of neurology
影响因子:
6
作者:
[Hares K, Kemp K, Loveless S, Rice CM, Scolding N, Tallantyre E, Robertson N, Wilkins A]
通讯作者:
Wilkins A
DOI:
10.1016/s1474-4422(17)30007-8
发表时间:
2017-04-01
期刊:
LANCET NEUROLOGY
影响因子:
48
作者:
[Kalincik, Tomas, Brown, J. William L., Coles, Alasdair]
通讯作者:
Coles, Alasdair
国内基金
海外基金
登录
查看更多内容
精氨酸调控骨髓Tregs稳态在脓毒症骨髓功能障碍中的作用研究
-
批准号:82371770
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:宁铂涛
-
依托单位:
骨髓ISG+NAMPT+中性粒细胞介导抗磷脂综合征B细胞异常活化的机制研究
-
批准号:82371799
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:杨程德
-
依托单位:
诱导骨髓间充质干细胞分化为单倍体雄性生殖细胞
-
批准号:81070530
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2010
-
负责人:崔光辉
-
依托单位:
骨髓基质干细胞体外构建耳廓形态软骨
-
批准号:30973131
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2009
-
负责人:周广东
-
依托单位:
山羊皮质脊髓束投射通路缺血性损伤动物模型建立以及MPA1B在BMSCs脊髓内迁移中的轴突导向作用机理
-
批准号:30972153
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2009
-
负责人:杨小玉
-
依托单位:
骨髓源干细胞参与周围神经再生的实验研究
-
批准号:30973050
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2009
-
负责人:祁佐良
-
依托单位:
骨髓间充质干细胞向肝脏星状细胞定向分化的构建及其在诱导同种异体胰岛细胞移植免疫耐受中的作用
-
批准号:30872484
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2008
-
负责人:尹震宇
-
依托单位:
MSC介导的抑止性T细胞级联在allo-BMT后GVHD中的作用与机制研究
-
批准号:30801051
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:赵智刚
-
依托单位:
微重力场中髓核细胞诱导骨髓间充质干细胞分化及永生化
-
批准号:30772206
-
项目类别:面上项目
-
资助金额:26.0万元
-
批准年份:2007
-
负责人:李锋
-
依托单位: